Abstract 4226: Genome-wide CRISPRi screening identifies histone modification as a synergistic partner with JAK/STAT inhibition for enhancing anti-tumor activity in CTCL, validated in PDX-derived tumor cells

Yan-Jin Liu(Institute of Biological Chemistry, Academia Sinica), Weiyun Z. Ai(City College of San Francisco), Laura Pincus(University of California, San Francisco), Frank McCormick(Frederick National Laboratory for Cancer Research), Haitao Wang(Wuhan University)
Cancer Research
April 21, 2025
10.1158/1538-7445.am2025-4226
Cited by 0

Related Papers

Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target
|Cancer Cell|2013|571
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487
Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China
|Hepatology|2020|448